Biscayne Neurotherapeutics is a clinical-stage biotechnology company developing novel drugs for serious central nervous system disorders such as refractory epilepsy. Biscayne's lead compound BIS-001 has shown striking efficacy in highly predictive models of difficult-to-treat epileptic conditions such as complex partial seizures and Dravet syndrome. Biscayne's technology is licensed from Harvard University, Yale University and the University of South Florida. Biscayne is headquartered in Miami, FL.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/27/17 | $3,000,000 | Series B |
GF Securities Mesa Verde Venture Partners Quark Venture | undisclosed |
